valproic acid has been researched along with Fatty Liver, Nonalcoholic in 10 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Both high fat diet (HFD) and valproic acid (VPA) interfere with mitochondrial β-oxidation of fatty acids, which subsequently triggers microvesicular fatty liver and hepatic dysfunction." | 7.79 | Dysregulations of UDP-glucuronosyltransferases in rats with valproic acid and high fat diet induced fatty liver. ( Cao, L; Chu, X; Guo, C; Hao, H; Wang, G; Wang, H; Xie, H; Zhang, L; Zhou, X, 2013) |
| "Valproic acid (VPA), as one of the most widely prescribed antiepileptic drugs (AED) for many types of epilepsy in adults and children, is associated with weight gain, alteration of adipocytokine homeostasis, insulin resistance and Non-Alcoholic Fatty Liver Disease (NAFLD)." | 7.79 | The novel insulin resistance parameters RBP4 and GLP-1 in patients treated with valproic acid: just a sidestep? ( Ebenbichler, CF; Laimer, M; Luef, G; Rauchenzauner, M; Salzmann, K; Sandhofer, A; Sturm, W; Tschoner, A; Walser, G; Wiedmann, M, 2013) |
| "Both high fat diet (HFD) and valproic acid (VPA) interfere with mitochondrial β-oxidation of fatty acids, which subsequently triggers microvesicular fatty liver and hepatic dysfunction." | 3.79 | Dysregulations of UDP-glucuronosyltransferases in rats with valproic acid and high fat diet induced fatty liver. ( Cao, L; Chu, X; Guo, C; Hao, H; Wang, G; Wang, H; Xie, H; Zhang, L; Zhou, X, 2013) |
| "Valproic acid (VPA), as one of the most widely prescribed antiepileptic drugs (AED) for many types of epilepsy in adults and children, is associated with weight gain, alteration of adipocytokine homeostasis, insulin resistance and Non-Alcoholic Fatty Liver Disease (NAFLD)." | 3.79 | The novel insulin resistance parameters RBP4 and GLP-1 in patients treated with valproic acid: just a sidestep? ( Ebenbichler, CF; Laimer, M; Luef, G; Rauchenzauner, M; Salzmann, K; Sandhofer, A; Sturm, W; Tschoner, A; Walser, G; Wiedmann, M, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (90.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Song, W | 1 |
| Yan, X | 1 |
| Zhai, Y | 1 |
| Ren, J | 1 |
| Wu, T | 1 |
| Guo, H | 1 |
| Song, Y | 1 |
| Li, X | 1 |
| Guo, Y | 1 |
| Cuykx, M | 1 |
| Claes, L | 1 |
| Rodrigues, RM | 2 |
| Vanhaecke, T | 2 |
| Covaci, A | 1 |
| Berndt, N | 1 |
| Bulik, S | 1 |
| Wallach, I | 1 |
| Wünsch, T | 1 |
| König, M | 1 |
| Stockmann, M | 1 |
| Meierhofer, D | 1 |
| Holzhütter, HG | 1 |
| Ehrlich, A | 1 |
| Tsytkin-Kirschenzweig, S | 1 |
| Ioannidis, K | 1 |
| Ayyash, M | 1 |
| Riu, A | 1 |
| Note, R | 1 |
| Ouedraogo, G | 1 |
| Vanfleteren, J | 1 |
| Cohen, M | 1 |
| Nahmias, Y | 1 |
| Zhang, L | 1 |
| Chu, X | 1 |
| Wang, H | 1 |
| Xie, H | 2 |
| Guo, C | 2 |
| Cao, L | 1 |
| Zhou, X | 1 |
| Wang, G | 1 |
| Hao, H | 1 |
| Zhang, LF | 1 |
| Liu, LS | 1 |
| Chu, XM | 1 |
| Cao, LJ | 1 |
| A, JY | 1 |
| Cao, B | 1 |
| Li, MJ | 1 |
| Wang, GJ | 1 |
| Hao, HP | 1 |
| Benet, M | 1 |
| Guzmán, C | 1 |
| Pisonero-Vaquero, S | 1 |
| García-Mediavilla, MV | 1 |
| Sánchez-Campos, S | 1 |
| Martínez-Chantar, ML | 1 |
| Donato, MT | 1 |
| Castell, JV | 1 |
| Jover, R | 1 |
| Branson, S | 1 |
| De Boe, V | 1 |
| Sachinidis, A | 1 |
| Rogiers, V | 1 |
| De Kock, J | 1 |
| Willebrords, J | 1 |
| Pereira, IV | 1 |
| Maes, M | 1 |
| Crespo Yanguas, S | 1 |
| Colle, I | 1 |
| Van Den Bossche, B | 1 |
| Da Silva, TC | 1 |
| de Oliveira, CP | 1 |
| Andraus, W | 1 |
| Alves, VA | 1 |
| Cogliati, B | 1 |
| Vinken, M | 1 |
| Rauchenzauner, M | 1 |
| Laimer, M | 1 |
| Wiedmann, M | 1 |
| Tschoner, A | 1 |
| Salzmann, K | 1 |
| Sturm, W | 1 |
| Sandhofer, A | 1 |
| Walser, G | 1 |
| Luef, G | 1 |
| Ebenbichler, CF | 1 |
1 review available for valproic acid and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research.
Topics: Animals; Biomarkers; Diet, High-Fat; Disease Models, Animal; Fatty Acids; Humans; Lipid Metabolism; | 2015 |
9 other studies available for valproic acid and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Probiotics attenuate valproate-induced liver steatosis and oxidative stress in mice.
Topics: Animals; Liver; Mice; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Probiotics; Valproic Acid | 2023 |
Metabolomics profiling of steatosis progression in HepaRG
Topics: Biomarkers; Chemical and Drug Induced Liver Injury; Chromatography, Liquid; Disease Progression; Hep | 2018 |
HEPATOKIN1 is a biochemistry-based model of liver metabolism for applications in medicine and pharmacology.
Topics: Algorithms; Carcinoma, Hepatocellular; Enzyme Inhibitors; Galactosemias; Hepatocytes; Humans; Kineti | 2018 |
Microphysiological flux balance platform unravels the dynamics of drug induced steatosis.
Topics: Cell Line; Hepatocytes; Humans; Lab-On-A-Chip Devices; Metabolic Flux Analysis; Non-alcoholic Fatty | 2018 |
Dysregulations of UDP-glucuronosyltransferases in rats with valproic acid and high fat diet induced fatty liver.
Topics: Animals; Diet, High-Fat; Fatty Liver; Gene Expression Regulation, Enzymologic; Glucuronosyltransfera | 2013 |
Combined effects of a high-fat diet and chronic valproic acid treatment on hepatic steatosis and hepatotoxicity in rats.
Topics: Animals; Bile; Biomarkers; Chemical and Drug Induced Liver Injury; Citric Acid Cycle; Diet, High-Fat | 2014 |
Repression of the nuclear receptor small heterodimer partner by steatotic drugs and in advanced nonalcoholic fatty liver disease.
Topics: Animals; CCAAT-Enhancer-Binding Protein-alpha; Cells, Cultured; Cyclosporine; Doxycycline; Fatty Liv | 2015 |
In vitro assessment of drug-induced liver steatosis based on human dermal stem cell-derived hepatic cells.
Topics: Cells, Cultured; Chemical and Drug Induced Liver Injury; Flow Cytometry; Gene Expression Regulation; | 2016 |
The novel insulin resistance parameters RBP4 and GLP-1 in patients treated with valproic acid: just a sidestep?
Topics: Adolescent; Adult; Aged; Anticonvulsants; Child; Diabetes Mellitus, Type 2; Fatty Liver; Female; Glu | 2013 |